Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Can berries enhance lipitor's cholesterol lowering effects?
Are there specific stretches to avoid while on lipitor?
Patent expiration eu dabrafenib?
Quartette side effects?
When will latisse patent expire?

Kadcyla from pharmacy manufacturing cell line?

See the DrugPatentWatch profile for Kadcyla

Kadcyla (ado-trastuzumab emtansine, T-DM1) is an antibody-drug conjugate. The antibody part, trastuzumab, is produced using Chinese hamster ovary (CHO) cells. The cytotoxic payload (DM1) is a synthetic maytansine derivative that is chemically conjugated to the antibody after it’s produced. The exact CHO cell clone used by the manufacturer isn’t typically disclosed publicly, but CHO-based production is standard for trastuzumab-containing products.



Other Questions About Kadcyla :

When can we expect kadcyla biosimilar approval? Kadcyla pct wo patent application? How successful is kadcyla in practice compared to biosimilars? Are kadcyla biosimilars undergoing clinical trials? Kadcyla patent expiration date 2023? What are the probable commercial manufacturing steps of kadcyla? Are there specific patient groups where kadcyla outperforms biosimilars?